Navigation Links
PG500 Series Presented at the AACR Annual Meeting in San Diego
Date:4/13/2008

BRISBANE, Australia, April 14 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL) (Nasdaq: PGLA) announced today that it had presented new data on its patented PG500 series of compounds at the annual American Association for Cancer Research (AACR) meeting being held in San Diego. The meeting brings together approximately 17,000 participants from around the world to discuss new and significant advances in the knowledge surrounding the causes, diagnosis, treatment and prevention of cancer.

The data presented shows that this series of heparan sulfate mimetic compounds have very strong inhibition of angiogenesis and metastasis and strong anti-tumor activity in some aggressive tumor models. The data firmly supports the continued pre-clinical development of this new series of compounds as anti-cancer agents.

PG545 has been chosen as the lead candidate for additional studies required to support an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). Dr. Anand Gautam, Vice President, Drug Discovery, stated, "PG545 was selected over and above other compounds based on a comprehensive target product profile incorporating aspects such as efficacy, pharmacokinetics, toxicology and ease of manufacture."

Depending upon the outcome of these further studies we expect to submit an IND application with the US-FDA late this calendar year, or early 2009.

About Progen: Progen Pharmaceuticals is a globally focused biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has operations in Australia and the US.

About the PG500 series: Progen has an innovative small molec
'/>"/>

SOURCE Progen Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioVascular Inc. Closes $10.87 Million Series C Financing
2. Globus Medical Raises $110 Million in Series E Financing Round
3. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
4. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
5. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
6. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
7. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
10. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
11. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... of injectable drug delivery systems, today announced an ... facilities in response to increasing demand from pharmaceutical ... During the fourth quarter of fiscal year 2014, ... expenditures and R&D above normal quarterly investments. ...
(Date:7/30/2014)... N.Y. , July 30, 2014 /PRNewswire-iReach/ -- ... -based medical device company, has announced today ... the velox CD™ Vascular Closure Device. Velox CD™ ... immediate hemostasis following percutaneous femoral procedures. The single ... broadly ranging in size from 5F to 8F.  ...
(Date:7/30/2014)... -- InnoPharma, Inc. today announced the first generic launch of ... injection), in Canada.  Olanzapine is indicated for the rapid ... schizophrenia or bipolar I mania. As the ... into an agreement with Sandoz Canada Inc., pursuant to ... market and distribute Olanzapine Injection in Canada ...
Breaking Medicine Technology:Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... Ill., Dec. 21, 2010 The American Veterinary Medical Association ... new federal guidelines on a useful and effective induction agent, ... making propofol a Schedule IV drug.  In a letter to ... the DEA keep this effective drug, which typically causes few ...
... Dec. 21, 2010 Based on its recent ... & Sullivan recognizes Cambridge, Mass.-based Semprus BioSciences with ... Award for Surface Functionalization Technologies . The company,s ... designed to reduce the complications associated with implanted ...
Cached Medicine Technology:AVMA Offers Important Guidance to DEA on New Controls for Induction Agent—Propofol 2Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences 2Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences 3
(Date:7/30/2014)... (PRWEB) July 30, 2014 Volunteers from ... to counter drug abuse this summer with massive distribution ... , You can find these volunteers on Strøget, the ... residents alike for its shopping and its ambiance, some ... on a typical summer day. , These activities ...
(Date:7/30/2014)... mutationslong known to fuel cancer as well as evolutionary ... rare events that occur randomly throughout the genome. , ... involves the formation of multiple mutations that arise simultaneously ... of clustered mutations are frequently found in regions where ... the journal Cell Reports , may one day ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
(Date:7/30/2014)... IN (PRWEB) July 30, 2014 ... the opening of its new Carmel office on July ... staff will finally be moving to the state-of-the-art suite, ... cozy and innovative space will allow for one-on-one patient ... cosmetic surgery experience. , Dr. Hamilton’s new office-suite ...
(Date:7/30/2014)... caught it early" is possibly the best news a ... diagnosis. Combating cancer in its earliest stages, when the ... body, gives patients the best chances of survival. ... forms of cancer are touted for saving lives through ... as a precautionary measure, especially for high-risk patients. But ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3
... common among prisoners than among the general population of Thailandone ... found that 25% of prisoners who agreed to be tested ... in the national population. ,But Thailands prisons, say ... and severe budgetary constraints that impede the effective delivery of ...
... have been deployed worldwide to provide early detection of ... ,New methods that improve the overall detection capabilities of ... most surveillance systems do not hold up when there ... by public-health crises and major public events, such as ...
... the Archives of Internal Medicine journal, Obese or overweight ... risk of developing tuberculosis than those at a normal ... poverty and undernutrition in both developed and developing countries. ... associated with a wide range of chronic degenerative conditions, ...
... of antidepressant medications known as selective serotonin reuptake inhibitors ... loss in older men and women. Selective serotonin ... that transports serotonin, a neurotransmitter involved in sleep and ... in bone as well, raising the possibility that SSRIs ...
... of Washington shows that the work intended for global ... . ,The research was conducted by a UW ... professor in the School of Public Health and Community ... and Sally Weatherford, finance and administration director of the ...
... section does not affect infants health. The babies delivered ... early in life according to a new study. ... Hong Kong researchers found that babies delivered by C-section ... visits during their first 18 months of life. ...
Cached Medicine News:Health News:Obesity is Related to Lower Tuberculosis Risk 2Health News:Antidepressents may Lower Bone Density in Older People 2Health News:Antidepressents may Lower Bone Density in Older People 3Health News:Global Health Enriching the States Economy 2Health News:C- Section Does Not Affect an Infants Health 2
This ENDOLOOP suture has a suture type - 0 PDSII and a 1.5 inch diameter....
... long ligature inserted into a plastic tube. The plastic ... the other. The suture protrudes from the narrow end ... knot which becomes secure after the device is activated. ... the scored end of the plastic tube. The scored ...
... Panel is an enzyme immunoassay used for ... (glutamate dehydrogenase) and toxin A in human ... an aid in the diagnosis of C. ... the Triage Microbiology product line, designed to ...
ELISA for the detection of C. difficile toxin A in stool specimens...
Medicine Products: